Drug-induced mucosal alterations observed during esophagogastroduodenoscopy

doi:10.3748/wjg.v30.i16.2220

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 16

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8328)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-9) series, Tables (1-1) series.

Item

Count

PDF

279

HTML

4428

Figures (1-9)

603

Tables (1-1)

510

Sum=5820

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

253

Download

754

Sum=1007

Publishing Process of This Article

Item

Count

Browse

340

Download

847

Sum=1187

Apr 28, 2024 (publication date) through Feb 26, 2026

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Apr 28, 2024; 30(16): 2220-2232
Published online Apr 28, 2024. doi: 10.3748/wjg.v30.i16.2220

Drug-induced mucosal alterations observed during esophagogastroduodenoscopy

Masaya Iwamuro, Seiji Kawano, Motoyuki Otsuka

Masaya Iwamuro, Seiji Kawano, Motoyuki Otsuka, Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan

Author contributions: Iwamuro M designed the study and wrote the paper; Iwamuro M and Kawano S collected the data; Kawano S and Otsuka M critically reviewed the manuscript for important intellectual content; and Otsuka M approved the manuscript.

Conflict-of-interest statement: Iwamuro M has received lecture fees from Otsuka Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., as well as grants from Taisho Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Abbott Japan Co., Ltd. Kawano S has received lecture fees from Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., AstraZeneca PLC, Viatris Inc., Zeria Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd., along with grants from Taisho Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Abbott Japan Co., Ltd. Otsuka M has received lecture fees from Chugai Pharmaceutical Co., Ltd., Gilead Sciences, Inc., Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, AbbVie GK, EA Pharma Co., Ltd., and Kowa Company, Ltd., along with grants from Taisho Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Abbott Japan Co., Ltd.

Corresponding author: Masaya Iwamuro, MD, PhD, Assistant Professor, Doctor, Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-Ku, Okayama 700-8558, Japan. pr145h2k@okayama-u.ac.jp

Received: December 24, 2023
Revised: January 24, 2024
Accepted: April 1, 2024
Published online: April 28, 2024
Processing time: 124 Days and 3.7 Hours

Core Tip

Core Tip: Various lesions associated with medication use are detected during esophagogastroduodenoscopy, including pill-induced esophagitis, desquamative esophagitis, deteriorating gastroesophageal reflux, chemotherapy-induced esophagitis, proton pump inhibitor-induced gastric mucosal changes, medication-induced gastric erosions and ulcers, pseudomelanosis of the stomach, olmesartan-related gastric mucosal inflammation, lanthanum deposition in the stomach, zinc acetate hydrate tablet-induced gastric lesions, immune-related adverse event gastritis, olmesartan-associated sprue-like enteropathy, duodenal pseudomelanosis, and lanthanum deposition. Endoscopists must diagnose these mucosal alterations by acquiring pertinent knowledge regarding medication-induced lesions, concomitant with inquiries concerning patient medication history.